Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
The three companies' decisions were spurred by concerns about potential for the bone disorder avascular necrosis.